Answers are grounded in this paper and cite their sources.
INTRODUCTION: Pulmonary vascular endothelial cell (EC) dysfunction drives various pulmonary vascular diseases (PVD). Conventional pharmacological treatments often lack specificity. Current gene therapies rely on viral vectors, which often pose a safety concern. To address these issues, there is a critical need for delivery systems that can specifically target the pulmonary endothelium to ensure safety and therapeutic efficacy. AREAS COVERED: This review covers the fundamental principles of designing nanoparticles (NPs) for endothelial targeting, focusing on overcoming biological barriers, the impact of NP physicochemical properties on organ selectivity and NP-EC interactions, and active targeting strategies using specific ligands for receptor-mediated targeting. We also discuss the challenges and future perspectives of translating NP technologies to patient care. Literature published between 2007 and 2026 was identified through searches of PubMed, Google Scholar, and Web of Science databases. EXPERT OPINION: Precision lung-directed therapies for PVD require overcoming complex biological barriers through a deeper understanding of NP interactions with different cells and organs. This involves optimizing fundamental physicochemical properties of NPs to ensure pulmonary accumulation while utilizing specific ligands to enhance cellular uptake. Achieving clinical translation requires comprehensive safety assessments, manufacturing scalability, and standardized regulatory pathways. New technologies offer promising tools for developing personalized pulmonary nanomedicines.
No takes yet. Share an insight, caveat, or question.
Deng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: